{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:46:48Z","timestamp":1768970808145,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010571","name":"Bundesministerium f\u00fcr Bildung, Wissenschaft, Forschung und Technologie","doi-asserted-by":"publisher","award":["01EO1503"],"award-info":[{"award-number":["01EO1503"]}],"id":[{"id":"10.13039\/501100010571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite progress in diagnosis and therapy of heart failure (HF), etiology and risk stratification remain elusive in many patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The My Biopsy HF Study (German clinical trials register number: DRKS22178) is a retrospective monocentric study investigating an all-comer population of patients with unexplained HF based on a thorough workup including endomyocardial biopsy (EMB).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>655 patients (70.9% men, median age 55 [45\/66] years) with non-ischemic, non-valvular HF were included in the analyses. 489 patients were diagnosed with HF with reduced ejection fraction (HFrEF), 52 patients with HF with mildly reduced ejection fraction (HFmrEF) and 114 patients with HF with preserved ejection fraction (HFpEF). After a median follow-up of 4.6 (2.5\/6.6) years, 94 deaths were enumerated (HFrEF: 68; HFmrEF: 8; HFpEF: 18), equating to mortality rates of 3.3% and 11.6% for patients with HFrEF, 7.7% and 15.4% for patients with HFmrEF and 5.3% and 11.4% for patients with HFpEF after 1 and 5\u00a0years, respectively. In EMB, we detected a variety of putative etiologies of HF, including incidental cardiac amyloidosis (CA, 5.8%). In multivariate logistic regression analysis adjusting for age, sex and comorbidities only CA, age and NYHA functional class III\u2009+\u2009IV remained independently associated with all-cause mortality (CA: HR<jats:sub>perui<\/jats:sub> 3.13, 95% CI 1.5\u20136.51; <jats:italic>p<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In an all-comer population of patients presenting with HF of unknown etiology, incidental finding of CA stands out to be independently associated with all-cause mortality. Our findings suggest that prospective trials would be helpful to test the added value of a systematic and holistic work-up of HF of unknown etiology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00392-023-02354-6","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T15:02:01Z","timestamp":1705330921000},"page":"737-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Etiologies and predictors of mortality in an all-comer population of patients with non-ischemic heart failure"],"prefix":"10.1007","volume":"113","author":[{"given":"S.","family":"G\u00f6bel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Hahad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"von Henning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Gaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. P.","family":"Schultheiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Escher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"M\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-2781","authenticated-orcid":false,"given":"P.","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"2354_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD Disease","year":"2018","unstructured":"Disease GBD, Injury I, Prevalence C (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789\u20131858","journal-title":"Lancet"},{"key":"2354_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ehf2.12296","volume":"5","author":"E Sotiriou","year":"2018","unstructured":"Sotiriou E, Heiner S, Jansen T, Brandt M, Schmidt KH, Kreitner KF, Emrich T, Schultheiss HP, Schulz E, Munzel T, Wenzel P (2018) Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all-comer population of patients with heart failure: a retrospective analysis. ESC Heart Fail 5:630\u2013641","journal-title":"ESC Heart Fail"},{"key":"2354_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726","journal-title":"Eur Heart J"},{"key":"2354_CR4","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1093\/eurheartj\/ehm456","volume":"28","author":"LT Cooper","year":"2007","unstructured":"Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 28:3076\u20133093","journal-title":"Eur Heart J"},{"key":"2354_CR5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ejhf.2190","volume":"23","author":"PM Seferovic","year":"2021","unstructured":"Seferovic PM, Tsutsui H, McNamara DM, Ristic AD, Basso C, Bozkurt B, Cooper LT Jr, Filippatos G, Ide T, Inomata T, Klingel K, Linhart A, Lyon AR, Mehra MR, Polovina M, Milinkovic I, Nakamura K, Anker SD, Veljic I, Ohtani T, Okumura T, Thum T, Tschope C, Rosano G, Coats AJS, Starling RC (2021) Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail 23:854\u2013871","journal-title":"Eur J Heart Fail"},{"key":"2354_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0002-9149(77)90101-1","volume":"40","author":"C Kawai","year":"1977","unstructured":"Kawai C, Kitaura Y (1977) New endomyocardial biopsy catheter for the left ventricle. Am J Cardiol 40:63\u201365","journal-title":"Am J Cardiol"},{"key":"2354_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(74)93204-8","volume":"1","author":"PJ Richardson","year":"1974","unstructured":"Richardson PJ (1974) King\u2019s endomyocardial bioptome. Lancet 1:660\u2013661","journal-title":"Lancet"},{"key":"2354_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1161\/CIRCULATIONAHA.109.924167","volume":"122","author":"A Yilmaz","year":"2010","unstructured":"Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, Hill S, Mahrholdt H, Voehringer M, Schieber M, Klingel K, Kandolf R, Bohm M, Sechtem U (2010) Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 122:900\u2013909","journal-title":"Circulation"},{"key":"2354_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ijcard.2016.12.103","volume":"230","author":"T Stiermaier","year":"2017","unstructured":"Stiermaier T, Fohrenbach F, Klingel K, Kandolf R, Boudriot E, Sandri M, Linke A, Rommel KP, Desch S, Schuler G, Thiele H, Lurz P (2017) Biventricular endomyocardial biopsy in patients with suspected myocarditis: feasibility, complication rate and additional diagnostic value. Int J Cardiol 230:364\u2013370","journal-title":"Int J Cardiol"},{"key":"2354_CR10","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1161\/CIRCULATIONAHA.13.001414","volume":"128","author":"C Chimenti","year":"2013","unstructured":"Chimenti C, Frustaci A (2013) Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period. Circulation 128:1531\u20131541","journal-title":"Circulation"},{"issue":"6","key":"2354_CR11","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1002\/ehf2.13006","volume":"7","author":"S Gobel","year":"2020","unstructured":"Gobel S, Schwuchow-Thonke S, Jansen T, Karbach S, Emrich T, Gori T, Knies F, Schulz E, Munzel T, Keller K, Wenzel P (2020) Safety of transradial and transfemoral left ventricular compared with transfemoral right ventricular endomyocardial biopsy. ESC Heart Fail 7(6):4015\u20134023","journal-title":"ESC Heart Fail"},{"key":"2354_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16:233\u2013270","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2354_CR13","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"AL Caforio","year":"2013","unstructured":"Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM, European Society of Cardiology Working Group on M and Pericardial D (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:2636\u20132648","journal-title":"Eur Heart J"},{"key":"2354_CR14","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/s41436-019-0582-2","volume":"21","author":"M Catchpool","year":"2019","unstructured":"Catchpool M, Ramchand J, Martyn M, Hare DL, James PA, Trainer AH, Knight J, Goranitis I (2019) A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy. Genet Med 21:2815\u20132822","journal-title":"Genet Med"},{"key":"2354_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1172\/JCI62862","volume":"123","author":"EM McNally","year":"2013","unstructured":"McNally EM, Golbus JR, Puckelwartz MJ (2013) Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest 123:19\u201326","journal-title":"J Clin Invest"},{"key":"2354_CR16","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1161\/CIRCULATIONAHA.121.058457","volume":"146","author":"AS Lota","year":"2022","unstructured":"Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP, Tayal U, Verdonschot J, Meena D, Owen R, de Marvao A, Iacob A, Yazdani M, Hammersley DJ, Jones RE, Wage R, Buchan R, Vivian F, Hafouda Y, Noseda M, Gregson J, Mittal T, Wong J, Robertus JL, Baksi AJ, Vassiliou V, Tzoulaki I, Pantazis A, Cleland JGF, Barton PJR, Cook SA, Pennell DJ, Garcia-Pavia P, Cooper LT Jr, Heymans S, Ware JS, Prasad SK (2022) Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy. Circulation 146:1123\u20131134","journal-title":"Circulation"},{"key":"2354_CR17","doi-asserted-by":"crossref","unstructured":"Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, Sinagra G, Emdin M and Rapezzi C (2022) Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail 24(12):2342\u20132351","DOI":"10.1002\/ejhf.2532"},{"key":"2354_CR18","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36:2585\u20132594","journal-title":"Eur Heart J"},{"key":"2354_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, Riley SJ, Subramanya V, Brown EE, Hopkins CD, Ononogbu S, Perzel Mandell K, Halushka MK, Steenbergen C Jr, Rosenberg AZ, Tedford RJ, Judge DP, Shah SJ, Russell SD, Kass DA, Sharma K (2020) Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail 8:712\u2013724","journal-title":"JACC Heart Fail"},{"key":"2354_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ehf2.13110","volume":"8","author":"K Lindmark","year":"2021","unstructured":"Lindmark K, Pilebro B, Sundstrom T, Lindqvist P (2021) Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail 8:745\u2013749","journal-title":"ESC Heart Fail"},{"key":"2354_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM (2021) Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 6:1267\u20131274","journal-title":"JAMA Cardiol"},{"key":"2354_CR22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s10554-016-0915-z","volume":"32","author":"Y Bennani Smires","year":"2016","unstructured":"Bennani Smires Y, Victor G, Ribes D, Berry M, Cognet T, Mejean S, Huart A, Roussel M, Petermann A, Roncalli J, Carrie D, Rousseau H, Berry I, Chauveau D, Galinier M, Lairez O (2016) Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging 32:1403\u20131413","journal-title":"Int J Cardiovasc Imaging"},{"key":"2354_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254104","volume":"16","author":"S Goland","year":"2021","unstructured":"Goland S, Volodarsky I, Fabricant Y, Livschitz S, Tshori S, Cuciuc V, Zilberman L, Fugenfirov I, Meledin V, Shimoni S, Josfberg S, George J (2021) Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. PLoS\u00a0One 16:e0254104","journal-title":"PLoS\u00a0One"},{"key":"2354_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/13506129.2019.1625322","volume":"26","author":"A Lopez-Sainz","year":"2019","unstructured":"Lopez-Sainz A, de Haro-Del Moral FJ, Dominguez F, Restrepo-Cordoba A, Amor-Salamanca A, Hernandez-Hernandez A, Ruiz-Guerrero L, Krsnik I, Cobo-Marcos M, Castro V, Toquero-Ramos J, Lara-Pezzi E, Fernandez-Lozano I, Alonso-Pulpon L, Gonzalez-Lopez E, Garcia-Pavia P (2019) Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. Amyloid 26:156\u2013163","journal-title":"Amyloid"},{"key":"2354_CR25","doi-asserted-by":"publisher","unstructured":"Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Hutt DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD, Hawkins PN and Moon JC (2016) Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 9(8):e005066. PMID:27511979. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.005066","DOI":"10.1161\/CIRCIMAGING.116.005066"},{"key":"2354_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaccao.2021.08.008","volume":"3","author":"AK Singal","year":"2021","unstructured":"Singal AK, Bansal R, Singh A, Dorbala S, Sharma G, Gupta K, Saxena A, Bhargava B, Karthikeyan G, Ramakrishnan S, Bisoi AK, Hote MP, Rajashekar P, Chowdhury UK, Devagourou V, Patel C, Ray R, Arawa SK, Mishra S (2021) Concomitant transthyretin amyloidosis and severe aortic stenosis in elderly Indian population: a pilot study. JACC CardioOncol 3:565\u2013576","journal-title":"JACC CardioOncol"},{"key":"2354_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","volume":"77","author":"C Nitsche","year":"2021","unstructured":"Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, Wollenweber T, Ahmed N, Thornton GD, Kelion AD, Sabharwal N, Newton JD, Ozkor M, Kennon S, Mullen M, Lloyd G, Fontana M, Hawkins PN, Pugliese F, Menezes LJ, Moon JC, Mascherbauer J, Treibel TA (2021) Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 77:128\u2013139","journal-title":"J Am Coll Cardiol"},{"key":"2354_CR28","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38:2879\u20132887","journal-title":"Eur Heart J"},{"key":"2354_CR29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","volume":"71","author":"PR Scully","year":"2018","unstructured":"Scully PR, Treibel TA, Fontana M, Lloyd G, Mullen M, Pugliese F, Hartman N, Hawkins PN, Menezes LJ, Moon JC (2018) Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol 71:463\u2013464","journal-title":"J Am Coll Cardiol"},{"key":"2354_CR30","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T, Costes B, Hagege AA, Donal E, Eicher JC, Slama M, Guellich A, Rappeneau S, Gueffet JP, Logeart D, Plante-Bordeneuve V, Bouvaist H, Huttin O, Mulak G, Dubois-Rande JL, Goossens M, Canoui-Poitrine F, Buxbaum JN (2016) Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 37:1826\u20131834","journal-title":"Eur Heart J"},{"key":"2354_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijcard.2019.07.051","volume":"300","author":"N Maurizi","year":"2020","unstructured":"Maurizi N, Rella V, Fumagalli C, Salerno S, Castelletti S, Dagradi F, Torchio M, Marceca A, Meda M, Gasparini M, Boschi B, Girolami F, Parati G, Olivotto I, Crotti L, Cecchi F (2020) Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 300:191\u2013195","journal-title":"Int J Cardiol"},{"key":"2354_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijcard.2020.12.044","volume":"329","author":"PF Vianello","year":"2021","unstructured":"Vianello PF, La Malfa G, Tini G, Mazzola V, Miceli A, Santolini E, Briano S, Porto I, Canepa M (2021) Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study. Int J Cardiol 329:144\u2013147","journal-title":"Int J Cardiol"},{"key":"2354_CR33","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","volume":"72","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M (2018) Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol 72:2040\u20132050","journal-title":"J Am Coll Cardiol"},{"key":"2354_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12265-019-09895-0","volume":"12","author":"I Zegri-Reiriz","year":"2019","unstructured":"Zegri-Reiriz I, de Haro-Del Moral FJ, Dominguez F, Salas C, de la Cuadra P, Plaza A, Krsnik I, Gonzalez-Lopez E, Garcia-Pavia P (2019) Prevalence of cardiac amyloidosis in patients with carpal tunnel syndrome. J Cardiovasc Transl Res 12:507\u2013513","journal-title":"J Cardiovasc Transl Res"},{"key":"2354_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1471-2407-10-105","volume":"10","author":"V Askoxylakis","year":"2010","unstructured":"Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J, Bischof M (2010) Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 10:105","journal-title":"BMC Cancer"},{"key":"2354_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251\u2013259","journal-title":"N Engl J Med"},{"key":"2354_CR37","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","volume":"33","author":"Meta-analysis Global Group in Chronic Heart F","year":"2012","unstructured":"Meta-analysis Global Group in Chronic Heart F (2012) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33:1750\u20131757","journal-title":"Eur Heart J"},{"key":"2354_CR38","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","volume":"175","author":"Y Gerber","year":"2015","unstructured":"Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL (2015) A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 175:996\u20131004","journal-title":"JAMA Intern Med"},{"key":"2354_CR39","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.1594","volume":"21","author":"NR Jones","year":"2019","unstructured":"Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ (2019) Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail 21:1306\u20131325","journal-title":"Eur J Heart Fail"},{"key":"2354_CR40","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","volume":"34","author":"SJ Pocock","year":"2013","unstructured":"Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN, Doughty RN and Meta-Analysis Global Group in Chronic Heart F (2013) Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 34:1404\u20131413","journal-title":"Eur Heart J"},{"key":"2354_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00392-018-1302-7","volume":"108","author":"J Zhang","year":"2019","unstructured":"Zhang J, Begley A, Jackson R, Harrison M, Pellicori P, Clark AL, Cleland JGF (2019) Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis. Clin Res Cardiol 108:119\u2013132","journal-title":"Clin Res Cardiol"},{"key":"2354_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00392-022-02076-1","volume":"112","author":"EM Screever","year":"2023","unstructured":"Screever EM, van der Wal MHL, van Veldhuisen DJ, Jaarsma T, Koops A, van Dijk KS, Warink-Riemersma J, Coster JE, Westenbrink BD, van der Meer P, de Boer RA, Meijers WC (2023) Comorbidities complicating heart failure: changes over the last 15 years. Clin Res Cardiol 112:123\u2013133","journal-title":"Clin Res Cardiol"},{"key":"2354_CR43","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(16)31713-5","volume":"390","author":"RG Weintraub","year":"2017","unstructured":"Weintraub RG, Semsarian C, Macdonald P (2017) Dilated cardiomyopathy. Lancet 390:400\u2013414","journal-title":"Lancet"},{"key":"2354_CR44","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJM199412083312307","volume":"331","author":"GW Dec","year":"1994","unstructured":"Dec GW, Fuster V (1994) Idiopathic dilated cardiomyopathy. N Engl J Med 331:1564\u20131575","journal-title":"N Engl J Med"},{"key":"2354_CR45","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.105.606509","volume":"114","author":"H Mahrholdt","year":"2006","unstructured":"Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U (2006) Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114:1581\u20131590","journal-title":"Circulation"},{"key":"2354_CR46","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/01.CIR.0000155616.07901.35","volume":"111","author":"U Kuhl","year":"2005","unstructured":"Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with \u201cidiopathic\u201d left ventricular dysfunction. Circulation 111:887\u2013893","journal-title":"Circulation"},{"key":"2354_CR47","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJM198504043121404","volume":"312","author":"GW Dec Jr","year":"1985","unstructured":"Dec GW Jr, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC, Johnson RA (1985) Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 312:885\u2013890","journal-title":"N Engl J Med"},{"key":"2354_CR48","first-page":"499","volume":"85","author":"A D'Ambrosio","year":"2001","unstructured":"D\u2019Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, Silvestri F, Di Sciascio G (2001) The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 85:499\u2013504","journal-title":"Heart"},{"key":"2354_CR49","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005352","author":"F Escher","year":"2017","unstructured":"Escher F, Kuhl U, Lassner D, Stroux A, Gross U, Westermann D, Pieske B, Poller W, Schultheiss HP (2017) High perforin-positive cardiac cell infiltration and male sex predict adverse long-term mortality in patients with inflammatory cardiomyopathy. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.116.005352","journal-title":"J Am Heart Assoc"},{"key":"2354_CR50","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","volume":"30","author":"A Frustaci","year":"2009","unstructured":"Frustaci A, Russo MA, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30:1995\u20132002","journal-title":"Eur Heart J"},{"key":"2354_CR51","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751\u20133757","journal-title":"J Clin Oncol"},{"key":"2354_CR52","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121:3420\u20133427","journal-title":"Blood"},{"key":"2354_CR53","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30:989\u2013995","journal-title":"J Clin Oncol"},{"key":"2354_CR54","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39:2799\u20132806","journal-title":"Eur Heart J"},{"key":"2354_CR55","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Dispenzieri A (2017) Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129:2111\u20132119","journal-title":"Blood"},{"key":"2354_CR56","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, Investigators A-AS (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"},{"key":"2354_CR57","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","volume":"43","author":"S Law","year":"2022","unstructured":"Law S, Bezard M, Petrie A, Chacko L, Cohen OC, Ravichandran S, Ogunbiyi O, Kharoubi M, Ganeshananthan S, Ganeshananthan S, Gilbertson JA, Rowczenio D, Wechalekar A, Martinez-Naharro A, Lachmann HJ, Whelan CJ, Hutt DF, Hawkins PN, Damy T, Fontana M, Gillmore JD (2022) Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. Eur Heart J 43:2622\u20132632","journal-title":"Eur Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02354-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T10:22:07Z","timestamp":1713435727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02354-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2354"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02354-6","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"assertion":[{"value":"23 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. TM, KK, MMG, OH, FE, MB and HPS report no conflict of interest. SG reports having received consultancy and lecture honoraria from Pfizer, AstraZeneca, ZOLL, Boehringer Ingelheim, Bristol-Myers Squibb, Alnylam and Novartis. TG has received grant support (CARIMA study) and speaker\u00b4s honoraria from Novartis, speaker\u00b4s honoraria from Boehringer Ingelheim, Daiichi-Sankyo, MSD, Pfizer, Bristol-Myers Squibb and Astra Zeneca. PW has received consultancy and lecture honoraria from Abbott, Abiomed, Astra Zeneca, Bayer, Boehringer-Ingelheim, CVRx, Daiichi-Sankyo, Novartis, Pfizer and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}